Adagene (ADAG) files 6-K on Third Arc Bio SAFEbody licensing pact

Rhea-AI Filing Summary

Adagene Inc. submitted a Form 6-K to furnish a press release about a new licensing agreement with Third Arc Bio. The agreement covers development of two masked CD3 T cell engagers that will use Adagene’s SAFEbody^® technology. Detailed commercial and financial terms are contained in the referenced press release, filed as Exhibit 99.1.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-
16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-39997

Adagene Inc.

4F, Building C14, No. 218

Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu Province, 215123

People’s Republic of China

+86-512-8777-3632

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x   Form 40-F ¨

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Adagene Inc.
	By:	/s/ Peter Luo
	Name:	Peter Luo
	Title:	Chief Executive Officer
Date: November 13, 2025

EXHIBIT INDEX

Exhibit		Description
99.1		Press release titled Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

FAQ

What did Adagene Inc. (ADAG) report in this Form 6-K?

Adagene reported that it furnished a press release as Exhibit 99.1. The release announces a licensing agreement with Third Arc Bio to develop two masked CD3 T cell engagers using Adagene’s SAFEbody^® technology platform.

Who is Adagene’s licensing partner mentioned in the November 2025 6-K?

The licensing partner is Third Arc Bio. Adagene’s Form 6-K indicates that a press release, filed as Exhibit 99.1, describes a licensing agreement between Adagene and Third Arc Bio focused on CD3 T cell engager therapeutics.

What technology is highlighted in Adagene’s agreement with Third Arc Bio?

The agreement highlights Adagene’s SAFEbody^® technology. According to the Form 6-K, two masked CD3 T cell engagers will be developed utilizing this technology, as described in the accompanying press release filed as Exhibit 99.1.

How many CD3 T cell engagers are covered by Adagene’s deal with Third Arc Bio?

The deal covers two masked CD3 T cell engagers. The Form 6-K notes that these two CD3-targeting molecules will be developed using Adagene’s SAFEbody^® technology under a licensing agreement detailed in the press release attached as Exhibit 99.1.

Where can investors find more details on Adagene’s licensing agreement in the 6-K?

More details are in Exhibit 99.1 to the Form 6-K. That exhibit is a press release titled “Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody^® Technology.”